A real-world comparison of relapse rates, healthcare costs and resource use among patients with multiple sclerosis newly initiating subcutaneous interferon beta-1a versus oral disease-modifying drugs
{{output}}
Background: Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings. Objective: ... ...
